Expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase in patients with colorectal cancer

Anticancer Research

Volumn 32, Issue 5, 2012, Pages 1757-1762

  Goto, Tetsuhiro ^a   Shinmura, Kazuki ^a   Yokomizo, Kazuaki ^a   Sakuraba, Kazuma ^a   Kitamura, Youhei ^a   Shirahata, Atsushi ^a   Saito, Mitsuo ^a   Kigawa, Gaku ^a   Nemoto, Hiroshi ^a   Sanada, Yutaka ^a   Hibi, Kenji ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

5 Fluorouracil; Colorectal cancer; Danenberg tumor profile method; Dihydropyrimidine dehydrogenase; Thymidine phosphorylase; Thymidylate synthase

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; MESSENGER RNA; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; UFT;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR LOCALIZATION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 84861484517     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fukui Y, Oka T, Nagayama S, Danenberg PV, Danenberg KD and Fukushima M: Thymidylate synthase, dihydropyrimidine dehydrogenase, orotate phosphoribosyltransferase mRNA and protein expression levels in solid tumors in large scale population analysis. Int J Mol Med 22: 709-716, 2008.
2. Kawakami K, Ruszkiewicz A, Bennett G, Moore J, Watanabe G and Iacopetta B: The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 9: 5860- 5865, 2003.
3. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and Danenberg PV: Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229, 1997. (Pubitemid 27419335)
4. Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP and Leichman CG: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 4: 1243-1250, 1998. (Pubitemid 28213336)
5. Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P and Catalano G: Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil. Clin Cancer Res 5: 1996-1999, 1999. (Pubitemid 29399249)
6. Bathe OF, Franceschi D, Livingstone AS, Moffat FL, Tian E and Ardalan B: Increased thymidylate synthase gene expression in liver metastases from colorectal carcinoma: implications for chemotherapeutic options and survival. Cancer J Sci Am 5: 34- 40, 1999.
7. Paradiso A, Simone G, Petroni S, Leone B, Vallejo C, Lacava J, Romero A, Machiavelli M, De Lena M, Allegra CJ and Johnston PG: Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer 82: 560-567, 2000. (Pubitemid 30085191)
8. Johnston PG, Fisher ER, Rockette HE, Fisher B, Wolmark N, Drake JC, Chabner BA and Allegra CJ: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640-2647, 1994. (Pubitemid 24379651)
9. Takenoue T, Nagawa H, Matsuda K, Fujii S, Nita ME, Hatano K, Kitayama J, Tsuruo T and Muto T: Relation between thymidylate synthase expression and survival in colon carcinoma, and determination of appropriate application of 5-fluorouracil by immunohistochemical method. Ann Surg Oncol 7: 193-198, 2000. (Pubitemid 30215157)
10. Edler D, Glimelius B, Hallström M, Jakobsen A, Johnston PG, Magnusson I, Ragnhammar P and Blomgren H: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002. (Pubitemid 34273259)
11. Findlay MPN, Cunningham D, Morgan G, Clinton S, Hardcastle A and Aherne GW: Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903-909, 1997. (Pubitemid 27110709)
12. Aschele C, Debernardis D, Tunesi G, Maley F and Sobrero A: Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6: 4797-4802, 2000. (Pubitemid 32110422)
13. Etienne MC, Chéradama S, Fischel JL, Formento P, Dassonville O, Renee N, Schneider M, Thyss A, Demard F and Milano G: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
14. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000. (Pubitemid 30226214)
15. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, Wadler S, Lenz HJ, Groshen S, Leichman L and Danenberg PV: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5- fluorouracil. Clin Cancer Res 4: 2371-2376, 1998. (Pubitemid 28477901)
16. Saito S, Tsuno N, Nagawa H, Sunami E, Zhengxi J, Osada T, Kitayama J, Shibata Y, Tsuruo T and Muto T: Expression of platelet-derived endothelial cell growth factor correlates with good prognosis in patients with colorectal carcinoma. Cancer 88: 42-49, 2000. (Pubitemid 30027677)
17. Japanese Society for Cancer of the Colon and Rectum: General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus The 7th Edition, Revised Version, Kanehara shuppan, 2009.
18. Lord RV, Salonga D, Dannnberg KD, Peters JH, DeMeester TR, Park JM, Johansson J, Skinner KA, Chandrasoma P, DeMeester SR, Bremner CG, Tsai PI and Danenberg PV: Teromerase reverse transcriptase expression in increased early in the Barret's metaplasia, dysplasia, adenocarcinoma sequence. J Gastointest Surg 4: 135-142, 2000.
19. Nagano H, Ichikawa W, Simizu M, Shirota Y, Nihei Z: Thymidylate synthase and dihydropyrimidine dehydrogenase gene expression in colorectal cancer using the Danenberg tumor profile method. Gan To Kagaku Ryoho 31: 889-892, 2004.
20. Kuramochi H, Hayashi K, Uchida K, Miyakura S, Shimizu D, Vallbohmer D, Park S, Danenberg KD, Takasaki K and Danenberg PV: Vascular endothelial growth Factor messenger RNA expression level is preserved in liver metastases compared with corresponding primary colorectal cancer. Clin Cancer Res 12: 29- 33, 2006.
21. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I and Lippert H: Comparison of 17,641 Patients With Right-and Left-sided Colon Cancer: Differences in Epidemiology, Perioperative Course, Histology, and Survival. Dis Col Rectum 53: 57-64, 2010.
22. Hemminki K, Santi I, Weires M, Thomsen H, Sundquist J and Bermejo JL: Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer 10: 688-693, 2010.
23. Meguid RA, Slidell MB, Wolfgang CL, Chang DC and Ahuja N: Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 15: 2388-2394, 2008.
24. Schoffski P: The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. AntiCancer Drugs 15: 85-106, 2004.
25. Lamont EB and Schilsky RL: The Oral Fluoropyrimidines in Cancer Chemotherapy. Clinical Cancer Res 5: 2289-2296, 1999. (Pubitemid 29437304)
26. Taguchi T: Clinical application of biochemical modulation in cancer chemotherapy; biochemical modulation of 5-FU. Oncology 54: 12-18, 1997.
27. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of an oral 5-fl uorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996. (Pubitemid 26276346)
28. Ishitsuka H, Miwa M, Ishikawa T, Ura M, Sawada N, Nishida M, Fukase Y, Yamamoto T, Mori K, Arasaki M, Umeda I and Shimma N: Capecitabine: an orally available fluoropyrimidine with tumor selective activity. Proc Am Assoc Cancer Res 36: 407, 1995.
29. Sobrero A, Kerr D, Glimelius B, Van Cutsem E, Milano G, Pritchard DM, Rougier P and Aapro M: New directions in the treatment of colorectal cancer: a look to the future. European J Cancer 36: 559-566, 2000. (Pubitemid 30156840)
30. Yamada Y, Yamamoto S, Ohtsu A, Suzuki Y, Nasu J, Yamaguchi K, Denda T, Tsuji A, Hara Y, Boku N and Gastrointestinal Oncology Study Group/Japan Clinical Oncology Group: Impact of dihydropyrimidine dehydrogenase status of biopsy specimens on efficacy of irinotecan plus cisplatin, S-1, or 5-FU as first-line treatment of advanced gastric cancer patients in JCOG9912. 2009 ASCO Annual Meeting, Abstract no. 4535, 2009.